Publications by authors named "Alyssa Nicotra"
Lancet Haematol
January 2019
Article Synopsis
- Patients with high-risk chronic lymphocytic leukaemia (CLL) or mantle cell lymphoma often don't benefit from ibrutinib alone, prompting research into a combination therapy with a new drug, umbralisib.
- The study involved 44 patients from five sites in the USA who received a daily dose of umbralisib and ibrutinib to assess the safety, tolerability, and maximum dose of the drugs.
- Results showed no serious side effects, with a recommended dose of 800 mg for umbralisib in combination with ibrutinib, and common mild side effects included diarrhea.
